Clinical and economic benefits of expanded access programs: should we strengthen these pharmacist-led initiatives?

Eur J Hosp Pharm. 2024 Dec 30:ejhpharm-2024-004258. doi: 10.1136/ejhpharm-2024-004258. Online ahead of print.

Authors

Marcella Mezza¹, Roberto Brunoro², Girolama Iadicicco³, Mariassunta Miscio³, Daniele Mengato³, Dario Gregori¹, Francesca Venturini³

Affiliations

¹ UBEP - Unità di Biostatistca, Epidemiologia e Sanità pubblica, Universita degli Studi di Padova, Padova, Veneto, Italy.
² Department of Hospital Pharmacy, Azienda Ospedale Universita Padova, Padova, Veneto, Italy roberto.brunoro@gmail.com.
³ Department of Hospital Pharmacy, Azienda Ospedale Universita Padova, Padova, Veneto, Italy.

PMID: 38871442
DOI: 10.1136/ejhpharm-2024-004258

No abstract available

Keywords: Cost-Benefit Analysis; Ethics, Pharmacy; Financial Management; Health Policy; PHARMACY SERVICE, HOSPITAL.

Publication types

Letter